Monoclonal antibody targeting HER2/ERBB2; inhibits signaling and mediates ADCC.
Humanized monoclonal antibody that binds HER2/ERBB2 on tumor cells, inhibits HER2 signaling and dimerization, and induces antibody‑dependent cellular cytotoxicity (ADCC) against HER2‑overexpressing cells.
Trastuzumab binds HER2 on tumor cells and recruits FcγR-expressing immune effectors (e.g., NK cells) to mediate antibody-dependent cellular cytotoxicity, with some complement-mediated lysis; this kills HER2+ cells.
Humanized monoclonal antibody against HER2 that binds the extracellular dimerization domain (subdomain II), blocking ligand-dependent HER2 heterodimerization—especially HER2:HER3—thereby inhibiting downstream PI3K/AKT and MAPK signaling, reducing proliferation and promoting tumor cell death; complements trastuzumab.
Pertuzumab binds HER2, blocks HER2:HER3 signaling to promote apoptosis, and its IgG1 Fc engages FcγR-bearing effector cells (e.g., NK cells) to mediate ADCC against HER2+ cells.
Trop-2–targeted antibody-drug conjugate consisting of the humanized anti–Trop-2 mAb (hRS7) linked via a hydrolyzable linker to SN-38 (active metabolite of irinotecan), delivering SN-38 to Trop-2–expressing tumor cells to induce DNA damage and cell death with a bystander effect.
Humanized anti–Trop-2 monoclonal antibody linked via a hydrolyzable linker to SN-38 (topoisomerase I inhibitor); binds Trop-2 on tumor cells, is internalized and cleaved to release SN-38, which stabilizes Topo I–DNA complexes to induce DNA damage and apoptosis, with a bystander killing effect.
Antibody–drug conjugate binds TROP2, is internalized, and releases SN-38 (topoisomerase I inhibitor) causing DNA damage and apoptosis; also enables bystander killing.
Recombinant humanized anti‑HER2 bispecific antibody–drug conjugate (ADC) that binds HER2 on tumor cells, is internalized, and releases the linked cytotoxic payload MMAE to inhibit tubulin polymerization; may also engage Fc‑mediated effector functions.
Bispecific anti-HER2 ADC that binds two non-overlapping HER2 extracellular epitopes (ECD2 and ECD4), is internalized, and releases the microtubule-disrupting payload MMAE to inhibit tubulin polymerization, leading to mitotic arrest and apoptosis; Fc-mediated effector functions may also contribute.
KM501 binds HER2 (ECD2/ECD4), is internalized, and releases MMAE that disrupts microtubules, causing mitotic arrest and apoptosis; Fc effector functions may also mediate ADCC.
Recombinant humanized anti‑HER2 bispecific antibody–drug conjugate (ADC) that binds HER2 on tumor cells, is internalized, and releases the linked cytotoxic payload MMAE to inhibit tubulin polymerization; may also engage Fc‑mediated effector functions.
Bispecific anti-HER2 ADC that binds two non-overlapping HER2 extracellular epitopes (ECD2 and ECD4), is internalized, and releases the microtubule-disrupting payload MMAE to inhibit tubulin polymerization, leading to mitotic arrest and apoptosis; Fc-mediated effector functions may also contribute.
ADC binds HER2 (ECD2/ECD4), is internalized, and releases MMAE to inhibit tubulin polymerization, causing mitotic arrest and apoptosis; Fc-mediated ADCC/CDC may also contribute.